Just another WordPress site

Cannabis Use Disorder and Its Treatment

Sep 27, 2022

Scientific advances and clinical epidemiology provide clear evidence of cannabis’ potential for addiction and adverse psychosocial and health consequences, yet skepticism about its addictive potential remains, and perceived risk of its potential for harm continues to decrease. Indeed, treatment seeking for cannabis use disorder (CUD) comprises a substantial proportion of all substance use treatment admissions. This chapter is focused on cannabis’ potential for misuse and addiction and reviews what is known about behavioral and pharmacological interventions for cannabis use reduction or cessation. Behavioral treatments, brief interventions, and digital health interventions have demonstrated efficacy, although there remains much room for continued improvement in outcomes. Unfortunately, a growing body of research has yet to identify an effective pharmacotherapy, and no medications are currently approved by the FDA for treating CUD. Continued efforts to identify and increase access to effective interventions for misuse and CUD are imperative to the public health considering the loosening of cannabis laws for both therapeutic and recreational use, the burgeoning of cannabis industry, and societal and cultural trends toward acceptance of cannabis use. The field will continue to benefit from efforts to develop innovative treatments that leverage scientific and technological advances and that better tailor interventions to individuals or subgroups of cannabis users.



Other Posts

Recommended Approaches to Evaluate Methodologies and Technologies for the Detection of Cannabis-Impaired Driving

In September 2023, New York State Department of Health (DOH) issued a Request for Information (RFI) regarding methodologies and technologies used for the detection and assessment of driving under-the-influence of cannabis (DUIC). The RFI purpose is to assist the DOH in assessing the current state of research on impairment due to cannabis ingestion, and to review current devices that can be used to detect impairment. Moreover, the DOH is seeking to identify research institutions in higher education that are currently performing this type of research.

read more

Maryland Medical Cannabis Patient Survey Report 2022

The Maryland Medical Cannabis Commission sponsored this survey and report from Cannabis Public Policy Consulting (CPPC) to examine patterns of use, perceptions of risk and benefit, and occurrence of high-risk
behaviors related to cannabis use in the medical cannabis patient population. More than 13,000 medical cannabis patients took part in the survey, which was conducted in September 2022, prior to the General Election referendum to legalize adult use in the state. A second, post referendum survey is planned for fall 2023.

read more